Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular characterization of ESR1 variants in breast cancer.

Breast cancer research and treatment - 1 Nov 2022

Heeke Arielle L, Elliott Andrew, Feldman Rebecca, O'Connor Hazel F, Pohlmann Paula R, Lynce Filipa, Swain Sandra M, Nunes Maria R, Magee Daniel, Oberley Matthew J, Swenson Jeffrey, Vidal Gregory, Isaacs Claudine, Schwartzberg Lee, Korn W Michael, Tan Antoinette R

Abstract excerpt

PURPOSE: Estrogen receptor 1 (ESR1) mutations and fusions typically arise in patients with hormone receptor-positive breast cancer after aromatase inhibitor therapy, whereby ESR1 is constitutively activated in a ligand-independent manner. These variants can impact treatment response. Herein, we characterize ESR1 variants among molecularly profiled advanced breast cancers. METHODS: DNA next-generation sequencing...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aromatase Inhibitors
Share to B7-H1 Antigen

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Breast Neoplasms

Share to Estrogen Receptor alpha

Share to Ligands

Share to Programmed Cell Death 1 Receptor

Share to Receptors, Androgen

Share to Receptors, Estrogen

Source

Identifiers

PMID: 36125660
DOI: 10.1007/s10549-022-06740-y

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular characterization of ESR1 variants in breast cancer.PMID 36125660Read ↗

Molecular Characterization of ESR1 Variants in Breast CancerSemantic proximity Read ↗

Characterization of ESR1 alterations in patients with breast and gynecologic cancers.Semantic proximity Read ↗

The Clinical Utility of ESR1 Mutations in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer.Semantic proximity Read ↗

Genomic and clinical landscape of metastatic hormone receptors-positive breast cancers carrying ESR1 alterations.Semantic proximity Read ↗

ESR1 activating mutations: From structure to clinical application.Semantic proximity Read ↗

ESR1 Fusions Invoke Breast Cancer Subtype-Dependent Enrichment of Ligand-Independent Oncogenic Signatures and Phenotypes.Semantic proximity Read ↗

Activating ESR1 mutations in hormone-resistant metastatic breast cancer.Semantic proximity Read ↗

Enrichment of kinase fusions in ESR1 wild-type, metastatic breast cancer revealed by a systematic analysis of 4854 patients.Semantic proximity Read ↗

ESR1 genetic alterations and their association with clinicopathologic characteristics in advanced breast cancer: a single academic institution experience.Semantic proximity Read ↗

Fusion Genes in Breast Cancer.Semantic proximity Read ↗

Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer.Semantic proximity Read ↗

Transcriptional Reprogramming Differentiates Active from Inactive ESR1 Fusions in Endocrine Therapy-Refractory Metastatic Breast Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.